DeLong Mark Jeffrey 4

What Happened
Mark DeLong, Apellis Pharmaceuticals' Chief Business & Strategy Officer, sold 368 shares on February 11, 2026 at $22.15 per share, for a total of $8,153. The Form 4 reports this as a sale (code S) and the filing notes the shares were sold to cover tax withholding related to restricted stock units released on February 10, 2026. This is a routine sale to satisfy tax obligations rather than a standalone market-timing purchase.

Key Details

• Transaction date: 2026-02-11; Price: $22.15 per share; Shares sold: 368; Proceeds: $8,153.
• Filing date / accession: Form 4 filed 2026-02-13 (appears timely for a Form 4).
• Footnote: Sale was to cover tax withholding on RSUs released Feb 10, 2026 (Footnote F1).
• Shares owned after transaction: Not specified in the provided summary of the filing.
• Transaction code: S (sale); footnote code F indicates tax withholding disposition.

Context
This was a tax-withholding sale following the release of RSUs — a common, routine insider transaction that doesn't necessarily indicate a change in the insider's view of the company. The trade size (~$8k) is small relative to typical executive holdings and should be interpreted accordingly.